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The generation of a potent humoral immune response by B cells relies on the integration
of signals induced by the B cell receptor, toll-like receptors and both negative and positive
co-receptors. Several reports also suggest that integrin signaling plays an important role
in this process. How integrin signaling is regulated in B cells is however still partially
understood. Integrin activity and function are controlled by several mechanisms including
regulation by molecular adaptors of the paxillin family. In B cells, Leupaxin (Lpxn) is the
most expressed member of the family and in vitro studies suggest that it could dampen
BCR signaling. Here, we report that Lpxn expression is increased in germinal center
B cells compared to naïve B cells. Moreover, Lpxn deficiency leads to decreased B
cell differentiation into plasma cells in vitro. However, Lpxn seems dispensable for the
generation of a potent B cell immune response in vivo. Altogether our results suggest
that Lpxn is dispensable for T-dependent and T-independent B cell immune responses.
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INTRODUCTION
B cells and plasma cells (PCs), corresponding to the terminal step of B cell differentiation, are
key players of humoral immunity. After activation by antigen, B cells can either differentiate
rapidly into PCs through the extrafollicular response or, following cooperation with T cells they
can generate germinal centers (GC). In this structure B cells have an intense proliferative activity
and are submitted to two genetic modification processes; somatic hypermutation (SHM) and class
switch recombination (CSR) to improve respectively the affinity and effector properties of their B
cell antigen receptor (BCR). The output of GCs is thus high-affinity and class-switched memory B
cells or PCs (1). B cell activation, GC formation, high affinity B cell selection and PC differentiation
rely on a tight regulation of the BCR signal strength (2–4). It is regulated by both positive and
negative co-signaling through co-receptors including CD19 or CD22 for example (5–9). Integrins,
although not co-receptors per se, play an important role in B cell activation. Integrins control B
cell migration and adhesion (10–12) but their role is not limited to slowing down B cells. They
also control the threshold of antigen-mediated signaling required for the full activation of B cells
notably via the VLA4/VCAM1 complex (13).
Integrin activity and signaling are controlled by several mechanisms including regulation by
the paxillin family of molecular adaptors (14). The paxillin family is composed of three members,
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Paxillin, Hic-5, and Leupaxin (Lpxn). This family presents a
strong conservation with characteristic 3–5 amino terminal
leucine-rich domain (LD)motifs and 4 Lin-11/Isl-1/Mec-3 (LIM)
domains in C-terminus (C-ter) that are known to mediate
protein-protein interactions (15). This family of molecular
adaptors is mainly involved in the regulation of the dynamics
of cellular adhesion via integrins. The two first members have
been well-described and their function is better characterized
than Lpxn (16). Indeed, Paxillin, and Hic5 were described in
integrin-mediated focal adhesion points where they contribute
to the recruitment of several proteins including MAPK leading
to the reorganization of the actin cytoskeleton (17). Hic5 does
not seem to be expressed in immune cells while Paxillin is mainly
expressed by granulocytes (based on the ImmGen database).
Lpxn expression was first reported in leukocytic cell lines (18)
before being observed in cancerous tissues and osteoclasts (19,
20).
Lpxn seems to regulate integrin activity through the control
of the phosphorylation of downstream adaptors. In the 293
cell line, Lpxn was shown to bind to PEST domain tyrosine
phosphatase (PEP), an intracellular protein tyrosine phosphatase,
implicated in the negative regulation of antigen receptor
signaling in lymphocytes (21). Notably it was demonstrated
that Lpxn via PEP participates to the dephosphorylation of
Pyk2 and Fak that are key transducers of the intregrin-induced
signaling cascade. Interestingly, Lpxn was also reported to
interact directly with Pyk2 (18). Moreover, in A20 and cos1
cell lines and splenocytes, Lpxn inhibits the Ras pathway that
is crucial during B cell activation (22, 23). Lpxn dysregulation
was also shown to participate to tissue invasion by promoting
cancerous cell adhesion and migration (19, 24). In addition,
an integrin-independent role for Lpxn in BCR signaling was
previously reported (25). In the human BJAB lymphoma cell
line Lpxn interacts with Lyn at the plasma membrane upon
BCR crosslinking. Moreover, Lpxn overexpression in the A20
B cell line decreased the BCR mediated phosphorylation of
JNK and p38 MAPK (25). More recently a transcriptomic study
suggested that Lpxn expression was under the control of the
transcription factor IRF8 that itself negatively regulates GC B
cells and PC differentiation (26). All these observations lead us
to interrogate the role of Lpxn in B cell activation, GC formation
and PC differentiation. Here, we report that Lpxn is more highly
expressed in GC B cells than in naïve B cells. Moreover, using
a total Lpxn deficient mouse model we showed that Lpxn is
required for efficient PC differentiation in vitro. However, Lpxn
seems to be dispensable for B cell activation in vivo.
MATERIALS AND METHODS
Mouse Model and Immunization
The Lpxn−/− mouse model was generated and provided by
The Sanger Institute Mouse Resource (Cambridge, UK). All
experiments were conducted in compliance with the European
Union guide for the care and use of laboratory animals and
has been reviewed and approved by an appropriate institutional
review committee (C2EA-26, Animal Care and Use Committee,
Villejuif, France) (approval number C9202301 project N◦026).
Immunization were performed intraperitoneally (ip) with 100µg
of 4-hydroxy-3-nitrophenylacetyl-keyhole limpet hemocyanine
(NP-KLH) (Biosearch Technologies) adjuvanted with alum
(Imject Alum, Thermo Scientific) for the first injection and with
100 µg NP-KLH in PBS for the second 28 days later or with
25 µg NP-LPS (Biosearch Technologies) in PBS. Blood samples
for each point of the kinetic were obtained by submandibular
puncture in accordance with maximum volume recommended
by the local ethical rule. Blood samples at sacrifice were obtained
by cardiac puncture immediately after euthanasia by inhalation
of carbon dioxide.
Cell Preparation and Flow Cytometry
Lymphoid organ cells [spleen, bone marrow, mesenteric lymph
nodes (mLN), inguinal lymph nodes (iLN), or Peyer’s patches
(PPs)] were isolated and stained as previously described (27).
Briefly, single cell suspensions were stained with appropriate
antibodies (Supplementary Table 1) in PBS supplemented with
2% BSA and 2mM EDTA for cell surface staining. Intracellular
staining was performed using the Foxp3/Transcription factor
staining buffer set (eBioscience) according to the provider
recommendation. Flow cytometry analyses were performed
on a BD LSR Fortessa cytometer and cell sorting experiments
for qPCR analysis were performed using a BD FACS AriaII
cell sorter. Data were analyzed with the Flowjo software
(TreeStar, Ashland, OR). Splenic B cell magnetic enrichments
for in vitro differentiation assay were performed using
the CD43 depletion kit (Miltenyi Biotec) according to the
manufacturer’s recommendations.
Western Blot Analysis
Splenocytes or the RAW264.7 cell line were resuspended in
RIPA lysis buffer supplemented with Protease and Phosphatase
Inhibitor (Thermofisher Scientific). Five or 30 µg of proteins
were separated on a NuPAGETM 4–12% Bis-Tris Gel (Invitrogen)
and transferred to a PVDF membrane. Primary antibodies
against Lpxn (provided by HO), paxillin family protein
(BD Biosciences) or β-actin (Cell Signaling) were incubated
overnight at 4◦C. Secondary antibodies, anti-rabbit IgG and
anti-mouse IgG1, respectively (Jackson Immuno Research and
Southern Biotech) conjugated to HRP were incubated 2 h
at room temperature. Proteins were detected using Pierce
ECL (Thermofisher Scientific) and signal was quantified by
ChemiDocTM Touch Gel Imaging System (BIO RAD). Band
intensity was measured with ImageJ, background was subtracted,
intensities were normalized to β-actin then to the WT
control group.
In vitro Cell Differentiation Assay
1 × 106 splenocytes or 0,5 × 106 B cells were stimulated
with 5µg/mL of lipopolysaccharide (LPS) (InVivoGen) with
or without 20 ng/mL of IL-4 (Miltenyi) or with 5µg/mL
anti-CD40 antibody (R&Dsystems) and 20 ng/mL of IL-4 for
3 days in RPMI supplemented with 10% fetal calf serum,
0.05mM 2-mercaptoethanol, 100 U/mL penicillin-streptomycin,
1mM sodium pyruvate, and non-essential amino acids as
recommended (Gibco). Supernatants were used for ELISA
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ELISA and ELISpot assays were performed as previously
described (28) for the determination of NP-specific antibody
titres and for the quantification of NP-specific antibody secreting
cells (ASCs), respectively. ELISA was also used for the detection
of total IgM secreted in culture supernatant. Briefly, plates were
pre-coated with goat anti-mouse IgM (Southern Biotech) or with
NP (4)-BSA/NP (15)-BSA (Biosearch Technologies). After a step
of saturation, 5 × 105 cells per well for ELISpot or diluted
sera/supernatants for ELISA were added before staining the fixed
antibodies with a peroxidase-conjugated secondary antibody.
Enzymatic revelation was performed with AEC (Sigma-Aldrich)
for the ELISpot and with the TMB substrate reagent set (BD
OptEIA) for ELISA. All Antibodies and the concentration used
are indicated in Supplementary Table 1.
Quantitative PCR
Total RNA was extracted using the RNeasy Mini kit (Qiagen).
Reverse transcription was performed using M-MLV reverse
transcriptase (Invitrogen) with (dT)25 primer (Invitrogen)
according to the supplier’s recommendations. Relative
quantification was performed with LightCycler Taqman
Master (Roche) on cDNA samples (20 ng per reaction).
Quantification of the gene of interest was performed as
previously described (29) by the 1Ct method with the mean of
Gapdh and Actin b used as housekeeper genes. TaqMan probes
for Gapdh (Mm99999915_g1), Actin b (Mm01205647_g), Aicda
(Mm01184115_m1), and Lpxn (Mm00547686_m1) (Applied
Biosystems) were used.
RESULTS
Lpxn Is Highly Expressed in Germinal
Center B Cells
Publicly available transcriptomic datasets suggest that, among
the B cell lineage, Lpxn is particularly highly expressed in
germinal center (GC) B cells (Supplementary Figure 1A). To
confirm this observation we sorted naïve B cells (B220+CD19+/
FASloGL7lo) and GC B cells (B220+CD19+/FAShiGL7hi) and
analyzed the expression of Lpxn on these two cell subsets
as well as on total splenocytes. The result obtained supports
that indeed Lpxn expression in GC B cells is at least 4 times
higher than in naïve B cells and 7 times higher than in total
splenocytes (Supplementary Figure 1B). As a positive control,
we also measured the expression of Aicda that is increased in GC
B cells compared to naïve B cells (30). In order to characterize
whether Lpxn plays a role in B cell activation and subsequently
on GC B cell biology we obtained a Lpxn deficient mouse model
created by the Sanger Institute Mouse Resource via a “knock-
out first” approach leading to the generation of a total knock-
out (31) (Supplementary Figure 2A). Lpxn transcript expression
was measured by qPCR on B cells from Lpxn+/+, Lpxn+/−, and
Lpxn−/− mice (Supplementary Figure 2B) confirming the total
TABLE 1 | Lpxn expression does not impact B cell ontogeny.
Lpxn+/+ Lpxn+/− Lpxn−/−
BM Pre- and pro-B cells 17.79 ± 3.38 15.56 ± 3.41 16.86 ± 2.39
Immature B cells 4.08 ± 0.74 3.10 ± 0.79 3.77 ± 0.74
Transitional B cells 0.16 ± 0.03 0.11 ± 0.04 0.12 ± 0.03
Mature B cells 5.61 ± 1.15 4.94 ± 1.17 4.82 ± 0.93
Spleen MZ B cells 7.4 ± 1.52 9.09 ± 1.49 6.67 ± 1.34
Follicular B cells 55.17 ± 0.68 53.37 ± 3.14 56.10 ± 4.31
B1a B cells 0.06 ± 0.008 0.05 ± 0.003 0.05 ± 0.01
B1b B cells 0.92 ± 0.034 1.02 ± 0.07 1.04 ± 0.10
The frequency of each B cell subset in the BM and spleen of Lpxn+/+, Lpxn+/−
or Lpxn−/− mice was determined by flow cytometry. BM B cell subsets were
gated as: B220low IgM− (pre- and pro-B cells), B220low IgMlow/+ (Immature B cells),
B220+ IgMlow/+ (Mature B cells), and B220low/+ IgM+ (Transitional B cells). Splenic
B cell subsets were gated as: B220+CD21lowCD23high (Follicular B cells) and
B220+CD21highCD23low [Marginal zone B cells (MZ)], CD19+B220−CD11b+CD5+ (B1a
B cells), and CD19+B220−CD11b+CD5− (B1b cells). The mean +/– the standard
error of the mean (sem) are shown. N = 3 mice in at least three independent
experiments. We did not observe significant difference between the three genotypes with
the two-tailed Mann-Whitney non-parametric test. The gating strategies are shown in
Supplementary Figure 3.
loss of expression of Lpxn in Lpxn−/− mice. Interestingly, we
observed an allele-dose dependent decrease in the expression
of Lpxn. Furthermore, we confirmed by western blot the allele-
dose dependent loss of Lpxn expression in Lpxn−/− mice
(Supplementary Figures 2C–E). In addition, Lpxn deficiency
was not associated with compensatory expression of Paxillin or
Hic-5 (Supplementary Figure 2E).
Lpxn deficiency did not affect spleen, Peyer’s patches (PP),
mesenteric lymph nodes (mLN), inguinal lymph nodes (iLN)
and bone marrow (BM) cellularity (Supplementary Table 2).
Moreover, the percentage of BM precursor B cells, immature B
cells, mature B cells and transitional B cells were comparable
between Lpxn+/+, Lpxn+/−, and Lpxn−/− mice (Table 1). In the
spleen, the frequency of marginal zone B cells, follicular B cells
and B1 cells of the three genotypes were also similar suggesting
that Lpxn is not necessary for B cell development (Table 1 and
Supplementary Figure 3 for the gating strategy).
Lpxn Expression Is Required for Plasma
Cell Differentiation in vitro
We next wanted to assess whether Lpxn deficiency affects B
cell activation and differentiation. For this we first analyzed
PC differentiation in vitro following B cell activation with
LPS. After 3 days of stimulation we observed that Lpxn−/−
B cells differentiated significantly less into PCs than their WT
and heterozygous counterparts (Figures 1A,B). This was also
observed when sorted B cells were used for in vitro differentiation
(Supplementary Figures 4A,B). Moreover, this decreased PC
differentiation was associated with decreased IgM production
(Figure 1C). This decrease was not due to a defect in B cell cycling
as shown by analyzing cell cycle with a Ki-67/DAPI staining after
1 and 2 days of stimulation (Figure 1D). PC survival was not
affected either by Lpxn deficiency (Figure 1E). Altogether, these
results suggest that Lpxn is important for B cell differentiation
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FIGURE 1 | Lpxn promotes PC differentiation in vitro. (A) Representative dot plots for PCs (gated as CD138highB220low) generated from Lpxn+/+, Lpxn+/−, and
Lpxn−/− splenocytes after 3 days of stimulation with LPS. (B) Quantification of the frequency of PCs generated from Lpxn+/+, Lpxn+/−, and Lpxn−/− splenocytes
after 3 days of stimulation with LPS. (C) ELISA quantification of total IgM secreted in the culture supernatant after 3 days of LPS stimulation. (D) The cell cycle status
of stimulated B cells was determined by flow cytometry. G0, G1, S, and G2/M cells were gated as DAPI−Ki-67−, DAPI−Ki-67+, DAPIintKi-67+, and DAPI+Ki-67+,
respectively. Lpxn+/+, Lpxn+/−, and Lpxn−/− mice are represented by black, blue and red lines, respectively. (E) The frequency of apoptotic PCs at day 3 post LPS
stimulation was determined by flow cytometry with an AnnexinV staining. For flow cytometry experiment cells were gated on their size and structure, on their viability
(Live/Dead zombie aqua staining) and doublets were excluded. N = 3–5 mice in at least three independent experiments. For (B), three experiments were pooled. For
(B,C,E) each symbol represents an individual mouse with the mean and the sem also represented. The p-values were determined with the two-tailed Mann-Whitney
non-parametric test. *p < 0.05; **p < 0.01. “ns” = non-significant p-value.
into PCs upon LPS stimulation but not for B cell proliferation
or PC survival. Strikingly, although they express significantly
less Lpxn than the wt mice, Lpxn+/− mice did not present an
alteration of PC differentiation suggesting the existence of a
threshold for Lpxn expression above which PC differentiation
occurs normally.
We next wondered whether Lpxn also affects B cell
differentiation following a T-dependent activation mimicked
in vitro through stimulation with an anti-CD40 Ab. Following
stimulation, however, PC differentiation was comparable
between the three groups of mice (Supplementary Figure 5A).
We also assessed whether Lpxn may be important for class-
switch recombination (CSR) by assessing CSR to the IgG1 isotype
after anti-CD40/IL-4 and LPS/IL-4 stimulation for 3 days. As
shown in Supplementary Figures 5B,C, the frequency of IgG1+
B cells was similar between Lpxn+/+, Lpxn+/−, and Lpxn−/−
mice in both conditions suggesting that Lpxn is dispensable for
IgG1 CSR.
Lpxn Is Dispensable for Germinal Center
and Plasma Cell Generation at Steady
State
Considering the increased expression of Lpxn in GC B cells
and the impact of Lpxn deficiency on B cell activation and PC
differentiation we next analyzed GC B cell and PC frequency
in the primary and secondary lymphoid organs of Lpxn+/+,
Lpxn+/−, and Lpxn−/− mice at steady state. B cell frequencies
in iLNs, mLNs, PPs, spleen, and BM were not affected by
Lpxn deficiency (Figures 2A,D). We observed a slight but
non-significant decrease in the frequency of GC B cells in
both mLNs and PPs of Lpxn−/− mice compared to Lpxn+/−
and Lpxn+/+ mice (Figure 2B). In parallel, we assessed T
cell help and showed that the frequency of Th2- (Gata3+),
Th17- (RORγT+) and Th1- (Tbet+) –biased T helper cells
were equivalent in Lpxn+/+, Lpxn+/−, and Lpxn−/− mice
(Supplementary Figure 6). Moreover, PC frequency was not
affected by Lpxn deficiency in any of the 5 tissues analyzed
(Figures 2C,E). Supporting this data, we observed that baseline
titres of circulating IgM and IgG1 were similar between the
three experimental groups (Figure 2F). Thus, at steady state
Lpxn expression does not seem essential for spontaneous GC
formation nor PC development.
Lpxn Is Not Essential for Plasma Cell
Generation After a T-Dependent
Immunization
To assess more precisely the impact of Lpxn on GC B cell
and PC differentiation in vivo we performed immunization
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FIGURE 2 | Lpxn is dispensable for germinal center and plasma cell generation at steady state. (A–E) Quantification of the frequency of B cells (A), GC B cells (B),
and PCs (C) in mesenteric lymph nodes (mLNs) (top row), Peyer’s patches (PPs) (second row), and inguinal LNs (iLNs) (third row), and frequency of B cells (D), and
PCs (E) in spleen (fourth row), and bone marrow (bottom row) at steady state. By flow cytometry B cells were gated as B220+, GC B cells as B220+GL7+Fas+ and
PCs as B220low/−CD138+. Cells were gated on their size and structure, on their viability (Live/Dead zombie aqua) and doublets were excluded. (F) ELISA
quantification of seric IgM (top) and IgG1 (bottom) in Lpxn+/+, Lpxn+/−, and Lpxn−/− mice at steady state. For all panels each symbol represents an individual mouse
with the mean and the sem also represented. Two or three experiments were pooled. The p-values were determined with the two-tailed Mann-Whitney
non-parametric test. All p-values were non significant (“ns”).
Frontiers in Immunology | www.frontiersin.org 5 March 2020 | Volume 11 | Article 466
Bonaud et al. Leupaxin in B Cell Responses
FIGURE 3 | Lpxn is not essential for plasma cell generation after a T-dependent immunization. (A) Schematic representation of the immunization protocol. NP-KLH
injections are indicated by black arrow and bleeding is indicated by lines. (B) ELISA quantification of seric NP4- (left panel) and NP15- (right panel) specific IgM and
IgG1 at each point in Lpxn+/+ (black line), Lpxn+/− (blue line), and Lpxn−/− (red line) mice. (C) Frequency of splenic PCs (B220low/−CD138+, top) and GC B cells
(B220+GL7+Fas+, bottom) determined by flow cytometry 7 days after boost. (D) Frequency of BM PCs (B220low/−CD138+) determined by flow cytometry 7 days
after boost. Cells were gated on their size and structure, on their viability (Live/Dead zombie aqua) and doublets were excluded. (E,F) Quantification of NP-specific IgM
and IgG1 ASCs from the spleen (E) and the BM (F) by ELISPOT. The affinity maturation was determined by calculating the ratio of NP4/NP15 ASCs in each condition
(right panels). Four independent experiments were pooled. The p-values were determined with the two-tailed Mann-Whitney non-parametric test. All p-values were
non significant (“ns”).
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FIGURE 4 | Lpxn is dispensable for T-independent plasma cell generation. (A) Representative dot plot of splenic PCs gated as B220low/−CD138+ 3 days after
NP-LPS immunization. (B) Percentage and absolute number (left and right, respectively) of splenic PCs determined by flow cytometry 3 days after NP-LPS
immunization. Cells were gated on their size and structure, on their viability (Live/Dead zombie aqua) and doublets were excluded. (C) ELISA quantification of seric
IgM at D3 after NP-LPS immunization. Two independent experiments were pooled. The p-values were determined with the two-tailed Mann-Whitney non-parametric
test. *p < 0.05; “ns” = non-significant p-value.
with the well-characterized T-dependent antigen NP-KLH to
induce a potent GC-mediated immune response in the spleen
(27, 32). Mice were immunized ip with NP-KLH in alum at
d0, boosted with NP-KLH only at day 28 and bled at day 3, 7,
14, 21, 28, and at sacrifice (Figure 3A). By ELISA, we observed
a normal kinetic of the immune response with a peak of Ig
secreted between day 14 and 21 post primary immunization
and a robust increase 7 days after the boost immunization
in the three experimental groups. Moreover, the level of NP-
specific IgM and IgG1 were similar for Lpxn+/+, Lpxn+/−,
and Lpxn−/− mice (Figure 3B, right). We also assessed the
quality of the response by measuring high affinity NP-specific
IgG (NP4 binding) and we did not observe difference between
the three groups (Figure 3B, left). At day 7 post boost we
analyzed by flow cytometry the percentage of GC B cells and
PCs in the spleen and BM of immunized animals. In agreement
with the ELISA data, the three experimental groups displayed
equivalent frequencies of total GC B cells and PCs in the spleen
and BM (Figures 3C,D and Supplementary Figure 7). Finally,
using ELISPOT, we analyzed at day 7 post boost NP-specific
Ab secreting cells (ASCs) in the spleen and BM (Figures 3E,F,
respectively). Again, we did not detect any difference between
the 3 genotypes in terms of NP-specific ASC frequency
(Figures 3E,F, left) nor affinity maturation as assessed by the
NP4/NP15 ratio (Figures 3E,F, right). In addition, a similar
result was obtained after sheep red blood cell immunization
(data not shown). Altogether, our in vivo data suggest that Lpxn
is dispensable for GC formation and PC differentiation after a
T-dependent immunization.
Lpxn Is Dispensable for T-independent
Plasma Cell Generation
As we observed a decreased PC differentiation in vitro after
LPS stimulation, we wondered if such a defect could be
observed in the frame of a T-independent immune response.
To verify this possibility we performed T-independent
immunization with NP-LPS and analyzed the generation
of PCs 3 days later. By flow cytometry we observed no
difference in the frequency or number of splenic PC between
Lpxn+/+, Lpxn+/−, or Lpxn−/− mice (Figures 4A,B).
Moreover, the titres of secreted IgM were equivalent in
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the sera of mice from the 3 genotypes (Figure 4C). Thus,
despite its clear impact in vitro, Lpxn appears not essential
for the development of a potent T-independent immune
response in vivo.
DISCUSSION
B cell activation relies on the integration of several signals
including BCR-antigen interaction and integrin-mediated
adhesion and signaling. Multiple reports in the literature hint
at a potential role for Lpxn in this process. Using a Lpxn full
knock-out mouse model we thoroughly investigated if this
was the case. Our results demonstrate that Lpxn is required
for efficient PC differentiation in vitro upon LPS stimulation.
Of note the gene dose effect observed for Lpxn expression
in Lpxn+/+, Lpxn+/−, and Lpxn−/− mice does not translate
into differential PC differentiation. In fact low level of Lpxn
expression, as observed in heterozygous mice, seems sufficient to
maintain a potent PC differentiation. However, immunization-
induced T-dependent and T-independent humoral responses
were normal in absence of Lpxn suggesting that this protein
is dispensable. In particular, we carefully analyzed GC B cells.
We initially showed that Lpxn is highly expressed in GC B
cells while the two other members of the family, Paxillin and
Hic-5 are barely detectable in this cell subset (as reported by
the ImmGen Consortium) (33). However, the kinetic and depth
of the GC B cell response was not affected by Lpxn deficiency.
We next wondered if the quality of this response might be
altered. We observed that Lpxn is dispensable for proper affinity
maturation. Finally, we also showed that in absence of Lpxn
PC generation was not affected after both T-dependent and
T-independent immunizations. The discrepancy observed
between our in vitro and in vivo results could have several causes.
First, Lpxn deficiency may impact differently different cell types.
Indeed we used a total Lpxn KO mouse model and we cannot
rule out a compensatory mechanism driven by the splenic
environment and not recapitulated in in vitro B cell cultures.
The generation of a B-cell specific conditional KO model could
be interesting to assess this point. Another possibility could be
that other members of the paxillin family compensate for Lpxn
deficiency in vivo. Indeed, although both Lpxn and Paxillin
regulate integrin-mediated cell adhesion and focal adhesion,
they appear to have distinct but interwoven roles (34). A direct
link may exist between Paxillin and Lpxn, with Lpxn acting
as a negative regulator of Paxillin in integrin-mediated cell
adhesion (35). Moreover, Hic5 is able to compensate for the
lack of Paxillin (36). We assessed the protein expression of
Paxillin and Hic5 in B cells from Lpxn+/+, Lpxn+/−, and
Lpxn−/− mice and observed that Hic5 was weakly expressed as
suggested by previous reports (ImmGen consortium) and that
their expression was not significantly affected by the loss of Lpxn
(Supplementary Figure 2E). Further work would be required
to determine whether Paxillin is sufficient to compensate for
Lpxn deficiency. Our results thus suggest that Lpxn is not
essential for B cell activation in vivo and that integrin regulation
in this cell type is likely to be independent of this molecule.
Whether other molecular mechanisms can compensate for
Lpxn deficiency will require further investigation. Taken
together, our results support a role for Lpxn in the generation
of PCs but some compensatory mechanisms are likely to
occur in vivo.
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